

PORTLAND HOLDINGS:

- ❖ Portland Holdings was founded by Michael Lee-Chin, a young immigrant from Jamaica over 30 years ago and today operates in over 20 countries, influencing approximately \$20 billion of assets globally.
- ❖ As owners and operators, with active influence over our portfolio businesses, Portland has a track record of accountability and creating wealth for clients/institutions/countries, having produced 7 billion-dollar companies across diverse sectors and geographies.
- ❖ Portland's mission of "Enabling Countries" seeks to provide governments and nations access to Canada's unique and extensive nuclear capabilities and clean energy technologies, as well as nuclear medicine with a core focus on precision oncology, to address humankind's greatest unmet needs. The group possesses the necessary strategic and execution capabilities to carry out international projects through local partners, and has the full breadth of expertise in structuring relevant operational and financing vehicles to execute broad mandates globally.

Michael Lee-Chin – Chairman of Portland Holdings:

- ❖ Michael Lee-Chin, President and Chairman of Portland Holdings, is widely regarded as a visionary entrepreneur whose philosophy of "doing well and doing good" has resulted in extraordinary business success and inspiring philanthropic initiatives. In addition to his duties across the Portland group of companies, Michael sits on various boards in Canada and throughout the Caribbean.
- ❖ Michael is a recipient of the Order of Jamaica, the country's highest national honors for outstanding service in business and philanthropy. He is also the recipient of the Queen Elizabeth II Diamond Jubilee Medal, and the Order of Ontario, the province's highest honor, for his contributions in various domains including healthcare, education, arts and culture. Michael sits on the Board of the Trust for the Americas, a development institution affiliated with the Organization of American States. He also serves as the Chair of the Government of Jamaica's Economic Growth Council.

CAPABILITIES AND PARTNERSHIPS:

NUCLEAR MEDICINE				
ITM Isotope Technologies Munich	OncoBeta GmbH	RadioMedix, Inc.	Telix Pharmaceuticals	Portland's In-house Capabilities
<p>Major ownership stake in ITM, a privately owned biotechnology and radiopharmaceutical group of companies based in Germany, with global industry centrality in targeted radionuclide therapy through the supply of:</p> <ul style="list-style-type: none"> • Diagnostic and therapeutic medical radioisotopes • Radiopharmaceuticals • Radiolabeling and quality control equipment <p>Through its affiliation with the International Centers for Precision Oncology (ICPO), ITM and Portland are operationalizing an international network of precision oncology centers around the world.</p>	<p>OncoBeta GmbH, headquartered in Garching, Germany, is a privately held medical device and radiochemical company specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications.</p> <p>OncoBeta's main product, Rhenium-SCT®, utilizes the Beta emitter radioisotope Rhenium-188 to painlessly treat non-melanoma skin cancer (NMSC), without the need for invasive surgery, therefore providing positive aesthetic outcomes.</p>	<p>Major ownership stake in RadioMedix, a Texas-based privately held clinical-stage biotechnology company developing targeted radiopharmaceuticals, with candidates at various stages of pre-clinical and clinical development, for the diagnosis, monitoring, and treatment of different types of cancers. The Company's most advanced program is AlphaMedix™ (²¹²Pb DOTAMTATE) therapy for the treatment of metastatic and unresectable somatostatin receptor positive neuroendocrine tumors, or NETs, a disease with a significant medical need.</p>	<p>Telix is a clinical-stage biopharmaceutical company, headquartered in Melbourne, Australia, that is focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) in oncology and rare diseases, including prostate, kidney, glioblastoma and hematologic cancers.</p>	<p>Portland's Life and Unifying Sciences division is led by some of the industry's most experienced technical and management professionals. Dr. Hubert Walinski is Portland's Chief Operating Officer, Dr. Ramon Arscott is Portland's Chief Medical Officer, and Dr. Randy Peterson is Portland's International Business Development Manager, Life Sciences. The business' mandate focuses on Targeted Radionuclide Therapies, and biotech and precision oncology companies advancing novel therapeutic and medical device technologies, and innovations globally.</p>

NUCLEAR ENERGY			
Canadian Nuclear Laboratories (CNL)	Ultra Safe Nuclear Corporation (USNC)	Atomic Energy of Canada Limited (AECL)	Portland's In-house Capabilities
<p>Portland has signed an MOU with CNL and is developing a collaborative partnership with CNL, a government-owned, contractor-operated (GoCo) entity, with the goal of addressing the following initiatives:</p> <ul style="list-style-type: none"> • Small Modular Reactors (SMRs) and advanced reactors • Nuclear and Environmental waste remediation • Hydrogen & Clean fuels • Radioisotopes • Full cycle support for nuclear power reactors • Globally unique breadth of knowledge for 'one-stop-shop' solutions to complex problems 	<p>Partnership agreement with Ultra Safe Nuclear Corporation (USNC), a global leader in:</p> <ul style="list-style-type: none"> • Fuels and materials for nuclear power, including TRISO, advanced moderators and Fully Ceramic Micro-encapsulated (FCM®) fuel • Small and very small reactors, including the Micro Modular Reactor (MMR®) for versatile and widespread zero-carbon terrestrial power production • Advanced nuclear technologies for space exploration <p>The agreement with USNC positions Portland as:</p> <ul style="list-style-type: none"> • Lead investor in USNC's Series B Funding • Exclusive holder of rights to jointly develop MMR projects in the MENA and the Caribbean regions • Exclusive holder of rights to jointly develop MMR regional manufacture and supply chains in the MENA and the Caribbean regions 	<p>Access to CNL's parent company, AECL, which is Canada's national nuclear agency, specializing in:</p> <ul style="list-style-type: none"> • Nuclear and science technology • Environmental stewardship • International best practices • Regulatory frameworks • Procurement and expenditure contracting processes 	<p>The team also includes Dr. Ken Petrunik, a global authority on the construction of nuclear reactors worldwide. He served as Chief Program Officer at the Barakah nuclear power plant in the UAE. In 2009, Dr. Petrunik retired from a 35-year career at Atomic Energy of Canada Limited (AECL) as the President of the CANDU Reactor Division, responsible for AECL's commercial CANDU business. Dr. Petrunik currently serves as Chairman of Global First Power working to construct and operate a Micro Modular Reactor® at CNL's facilities and has an advisory role to several international nuclear companies.</p> <p>The team also includes Dr. Ken Petrunik, a global authority on the construction of nuclear reactors worldwide. He served as Chief Program Officer at the Barakah nuclear power plant in the UAE. In 2009, Dr. Petrunik retired from a 35-year career at Atomic Energy of Canada Limited (AECL) as the President of the CANDU Reactor Division, responsible for AECL's commercial CANDU business. Dr. Petrunik currently serves as Chairman of Global First Power working to construct and operate a Micro Modular Reactor® at CNL's facilities and has an advisory role to several international nuclear companies.</p>

Portland Group as a gateway for all nuclear/clean energy and nuclear medicine engagements:

- ❖ Portland has a track record of mandated accountability and can offer a “one-stop” solution for a country's comprehensive needs in the areas of nuclear/clean energy and nuclear medicine. As an owner/operator, with a proven track record of operating in over 20 countries, Portland is committed to pursuing a nation-building approach to doing business by providing solutions to companies, industries, governments and nations, enabling them to invest in best-in-class talent and intellectual property in areas that are critical to their future, thus helping them become strong, sustainable, and independent.
- ❖ Portland is planning investment funds that will focus on investing in companies/IP/talent that cater to a broad range of technologies that are critical to various clean energy mandates. Through CNL, Portland has visibility into the technology landscape as well as superior technical due diligence capabilities given CNL's extensive domain expertise. As an established global investment firm, with a distinguished investing track record, Portland will be able to provide clients, institutions, family offices and sovereign wealth funds in any country, a unique opportunity to co-invest in technologies that will be critical to the country's future.

Access to Research & Development - Canadian Nuclear Laboratories (CNL):

- ❖ Portland and CNL have established a collaborative partnership which allows Portland the mandate for international commercialization for a broad range of nuclear technologies through CNL. The partnership aims to create a collaborative framework between Portland and CNL to cooperate on a range of projects to accelerate the development, optimization and access to clean energy, medical isotopes, and targeted radionuclide therapies to the global community. Portland has access to demanders that are seeking solutions globally, via its extensive network and relationships across various industries and is therefore ideally positioned to bring specific opportunities to CNL where the

two entities can leverage their respective capabilities and expertise to find long term solutions to problems that would be considered mankind's biggest unmet needs.

- ❖ As Canada's national nuclear laboratory with 70 years of experience, CNL is a repository of best-in-class technologies and IP, that is home to 1,600 engineers, 600 scientists, as well as researchers that received Nobel Prizes for their work at CNL. Operating a total of 17 nuclear facilities, CNL is a globally unique institution capable of providing nations with full-cycle nuclear solutions to complex long term nuclear and clean energy mandates.

Access to Nuclear Fuel Technology & Micro Modular Reactors - Ultra Safe Nuclear Corporation (USNC):

- ❖ Portland has entered into an exclusive agreement with USNC, a global leader and vertical integrator of nuclear technologies and services, through their Micro Modular Reactor (MMR®), Fully Ceramic Micro-encapsulated (FCM®) nuclear fuel, and nuclear power and propulsion technologies for space exploration.
- ❖ USNC is the only private company producing TRISO and FCM fuel which will enable the transformation of key power and industrial sectors around the world through advanced materials using strict inherent and intrinsic safety principles to drive innovation in fuels, materials, and design.
- ❖ USNC is demonstrating MMR Energy Systems at the Canadian Nuclear Laboratories with Ontario Power Generation (OPG) and the MMR at the University of Illinois at Urbana-Champaign. New deployment projects are underway in the United States, Canada, and Europe.
- ❖ Portland's partnership with USNC encompasses the following:
 - Participation as Lead Investor in USNC's Series B Funding for a total value up to US\$350 million.
 - Appointment of Michael Lee-Chin, Chairman of Portland Holdings, to the USNC board of directors.
 - Exclusive rights for the UAE in commercialization, use, distribution, marketing, selling, and sublicensing of USNC technology products through local or international partnerships with local government agencies, utility and power companies, and private industry stakeholders.
- ❖ Through its association with CNL, AECL and OPG, Portland has exclusive access to technical due diligence findings from these stakeholders into USNC's reactor technology and capabilities.